Ocular Therapeutix (OCUL) PT Raised to $24 at Cantor Fitzgerald on DEXTENZA Approval

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. SPY
7. CVS
8. UNH
9. SBUX
10. AXP

Go back to Ocular Therapeutix (OCUL) PT Raised to $24 at Cantor Fitzgerald on DEXTENZA Approval

Ocular Therapeutix (OCUL) PT Raised to $11 at Raymond James

December 3, 2018 1:20 PM EST

Raymond James analyst Dane Leone raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $11.00 (from $10.00) while maintaining a Strong Buy rating following FDA approval.

... More

Ocular Therapeutix (OCUL) Announces FDA Approval of DEXTENZA for Treatment of Ocular Pain

December 3, 2018 7:01 AM EST

Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use for the treatment of ocular pain following ophthalmic surgery.

We are extremely pleased to announce the approval of DEXTENZA, coming so soon after our pre-approval inspection and... More